Skip to content

Smoking Cessation and Menstrual Cycle Phase

Coordinating Smoking Cessation Treatment With Menstrual Cycle Phase to Improve Quit Outcomes: A Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05515354
Acronym
MC-NRT
Enrollment
1200
Registered
2022-08-25
Start date
2022-11-30
Completion date
2026-12-31
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence, Nicotine Use Disorder, Smoking Cessation, Substance Use Disorders, Tobacco Smoking

Keywords

Menstrual Cycle, Ovarian Hormones, Smoking Cessation Treatment, Nicotine Replacement Therapy, Cancer Prevention, Randomized Controlled Trial, Estrogen, Progesterone

Brief summary

Tobacco use is a risk factor for at least 20 types of cancer and remains the leading preventable cause of cancer in Canada. Smoking cessation is an important cancer prevention strategy for the close to 2 million Canadian women who currently smoke. However, findings from controlled trials and real-world clinical settings indicate that women have greater difficulty achieving abstinence following a quit attempt than men. There is some evidence that hormonal levels and fluctuations throughout the menstrual cycle (MC) may contribute to the greater difficulty women experience when trying to quit smoking. In this study, the start of a quit attempt using nicotine replacement therapy (NRT) will be targeted to specific phases of MC. It was hypothesized that starting a quit attempt during the first half of MC (follicular phase) will result in increased quit success compared to starting during the second half of MC (luteal phase) or the usual practice of not targeting quit start date to MC phase.

Detailed description

Evidence for the influence of the menstrual cycle (MC) phase on smoking cessation outcomes is contradictory and has been limited by small samples and a lack of clarity surrounding ideal quit date timing. Therefore, this large rigorously designed study aims to clarify whether targeting quit date to either the follicular or luteal phase of MC improves quit success. The primary hypothesis states that participants assigned a TQD in the follicular phase of their MC will be more likely to have quit successfully on day 7 of treatment than participants setting their own TQD (usual care). Quit rates at the end of treatment and 6 months post-TQD were identified as secondary objectives. Participants will enroll in an online smoking cessation program providing nicotine replacement therapy (NRT) and behavioral support. Participants will receive a 6-week supply of NRT consisting of nicotine patch plus their choice of nicotine gum or lozenge, which the participants will be instructed to start on their target quit date (TQD). Eligible individuals will be randomized to a TQD: \[1\] during the mid-luteal phase of their MC (6-8 days pre-onset of menses), \[2\] during the mid-follicular phase of their MC (6-8 days post-onset of menses), or \[3\] within 30 days of enrollment with no regard to MC phase (usual care). Behavioural support will consist of a free downloadable app (My Change Plan) and brief videos delivered via e-mail. These videos will be produced by the CAMH Nicotine Dependence Service and will focus on health behavior change strategies such as building a quit plan, coping with cravings, and relapse prevention.

Interventions

OTHERTiming of nicotine replacement therapy start date

Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.

Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.

Sponsors

Centre for Addiction and Mental Health
Lead SponsorOTHER
Canadian Cancer Society (CCS)
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Must provide informed consent following the CAMH REDCap e-consent framework and procedures; * Stated willingness to comply with all study procedures; * Naturally cycling individuals with regular MCs (defined as length ranging 21 to 35 days over past 6 months); * Daily smoker of ≥5 cigarettes per day (CPD) over past 6 months; * Intention to quit smoking within the next 30 days and willing to make a quit attempt on their assigned TQD; * Interested in using, and able to use, nicotine patches and gum or lozenge as a smoking cessation aid; * Willing to provide a valid e-mail address to be used for study communications and to complete online questionnaires.

Exclusion criteria

* Current use of progesterone, estrogen, testosterone, or fertility treatment; * Current use of nicotine replacement therapy or other smoking cessation medications (e.g., varenicline, bupropion); * Use of hormonal contraceptives in the past 6 months (e.g., pill, patch, hormonal intrauterine device \[IUD\], ring); * Pregnancy, or trying to become pregnant in the next 2-3 months; * Known hypersensitivity or allergies to any of the components of the nicotine patch; * Daily or almost daily use of cannabis in the past 6 months; * Daily or almost daily use of tobacco or nicotine products other than cigarettes (e.g., smokeless tobacco, heat-not-burn products, e-cigarettes) in the past 6 months; * Polycystic ovary syndrome diagnosis; * Unstable psychiatric condition (including substance use disorder) which would compromise study compliance; * Life threatening arrhythmias or severe/worsening angina pectoris; * Myocardial infarction or cerebral vascular accident in the past 2 weeks; or * Diagnosed with a terminal illness.

Design outcomes

Primary

MeasureTime frameDescription
7-day point prevalence of abstinence7 days post-target quit dateProportion of the sample that has been abstinent from smoking for 7 days at the time of assessment (i.e., managed to quit smoking on their target quit date).

Secondary

MeasureTime frameDescription
End-of-treatment 7-day point prevalence of abstinence6 weeks post-target quit dateProportion of the sample that has been abstinent from smoking for at least 7 days at the time of assessment.
Follow-up 7-day point prevalence of abstinence6 months post-target quit dateProportion of the sample that has been abstinent from smoking for at least 7 days at the time of assessment.

Countries

Canada

Contacts

CONTACTLaurie A Zawertailo, PhD
laurie.zawertailo@camh.ca4165358501
CONTACTTina Kabir, BMSc
tina.kabir@camh.ca4165358501
PRINCIPAL_INVESTIGATORLaurie A Zawertailo, PhD

Centre for Addiction and Mental Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026